Shares of Virios Therapeutics, Inc. (VIRI) are rising more than 14% Wednesday morning.
The company today said the data from the Phase 2a study of its investigational antiviral therapy IMC-1 in fibromyalgia showed that IMC-1 was better tolerated than placebo in patients with fibromyalgia.
Fibromyalgia is a chronic rheumatic condition that causes pain throughout the body.
The company said, this result is highlighted in a poster presentation at the International Association for the Study of Pain (IASP) World Congress, being held virtually June 9 - 11, 2021 and June 16 - 18, 2021.
VIRI is currently at $6.41. It has traded in the range of $4.60- $16.71 in the last one year.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.